OPKO Health, Inc. , has completed patient recruitment in the second phase 3 trial of Rayaldy TM to treat patients with secondary hyperparathyroidism , stage 3 or 4 chronic kidney disease and vitamin D insufficiency.
http://www.businesswire.com/news/topix/20131219005108/en
http://www.businesswire.com/news/topix/20131219005108/en
No comments:
Post a Comment